Mirum’s brelovitug succeeds in Phase 2b HDV trial

Mirum Pharmaceuticals ( (MIRM) ) has issued an announcement.

On April 27, 2026, Mirum reported that the Phase 2b portion of its AZURE-1 study in chronic hepatitis delta virus met its primary endpoint, with brelovitug showing strong antiviral activity and meaningful alanine aminotransferase normalization at Week 24. In 53 patients, virologic response reached 100% in the 300 mg once-weekly arm and 75% in the 900 mg every-four-weeks arm versus 0% with delayed treatment, and the drug was generally well tolerated with no treatment-related serious adverse events or discontinuations.

These data support brelovitug’s potential as a single-agent therapy for HDV and strengthen Mirum’s position in the competitive liver disease space as it advances to late-stage development. Full Phase 2b results will be presented at the European Association for the Study of the Liver Congress in May 2026, while Phase 3 AZURE-1 and AZURE-4 topline data are expected in the second half of 2026, setting up a potential U.S. biologics license application filing and commercial launch in 2027, which could materially expand the company’s future revenue base if successful.

The most recent analyst rating on (MIRM) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.

Spark’s Take on MIRM Stock

According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.

The score is driven primarily by improving fundamentals—rapid sales growth, high gross margins, and newly positive operating/free cash flow—tempered by still-negative profitability and meaningful leverage. The earnings call supports the outlook with continued growth guidance and a stronger cash position, but higher planned R&D spend and clinical/regulatory execution risk raise near-term uncertainty. Technical signals are mixed, and valuation is constrained by the negative P/E and no dividend.

To see Spark’s full report on MIRM stock, click here.

More about Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for serious liver diseases. Its pipeline includes investigational treatments such as brelovitug, a monoclonal antibody targeting hepatitis B surface antigen, aimed at addressing unmet needs in chronic viral hepatitis, including hepatitis delta virus infections.

Average Trading Volume: 812,951

Technical Sentiment Signal: Buy

Current Market Cap: $5.52B

For an in-depth examination of MIRM stock, go to TipRanks’ Overview page.